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ABSTRACT
Corydalis saxicola Bunting, also named Yanhuanglian in China, is widely used in folk prescriptions to treat hepatitis, hepatocirrhosis and hepatic cancer. Its active components consists mainly of alkaloids, which have poor solubility in water. The previous
study showed that the absolute bioavailabilities (BA) of the alkaloids were only about 10% after oral administration to rats,
compared to intravenous administration. In this paper, the solid dispersion (SD) method was used to improve the BAs of dehydrocavidine (YHL-1), coptisine (YHL-2), and dehydroapocavidine (YHL-3), the main alkaloids of the extract of Corydalis saxicola
Bunting, by improving their solubility. The results showed that using PEG 4000 as a carrier at an amount equivalent to 7 folds of the
extract could significantly improve the solubility of the compounds in water, pH 1.2 HCl and pH 7.2 PBS. DSC and X-ray detection
indicated that the drug might be in a dissolved or amorphous state in SD, which was different from that in the physical mixture. The
formulation was further studied in terms of BA enhancement by cumulative urinary excretion after oral administration to rats. A
new method using high performance liquid chromatography (HPLC) coupled to a diode-array detector (DAD) was established. The
results showed that the relative BAs (RE BAs) of YHL-1, YHL-2 and YHL-3 were all significantly improved by about 1 fold after
oral administration of SD solution, compared to the extract suspension (p < 0.05).
Key words: alkaloid, Corydalis saxicola Bunting, solid dispersion, bioavailability, HPLC

INTRODUCTION
Corydalis saxicola Bunting, also named Yanhuanglian in China, is mainly distributed in Guangxi Province and Guizhou Province, where it is widely used in
folk prescriptions to treat hepatitis, hepatocirrhosis and
hepatic cancer (1-3). Its active components mainly consists
of alkaloids, such as dehydrocavidine, coptisine, oxyacanthine, allocryptopine, berberine, tetrahydropalmatine, palmatine, dehydroapocavidine and tetradehydroscoulerine (4). Cheng et al. simultaneously determined
eight bioactive alkaloids in Corydalis saxicola using high
performance liquid chromatography coupled with diodearray detection (HPLC/DAD)(5). The alkaloids of Corydalis saxicola are mainly administered by injection. It
may be more convenient and patient compliance may be
improved if oral preparations were developed. The risk
of adverse reactions from injection can also be avoided.
Unfortunately, Li et al. studied the pharmacokinetics of
* Author for correspondence. Tel: +86-10-62797450;
Fax: +86-10-62772263; E-mail: liuqf@mail.tsinghua.edu.cn

the four main alkaloids after intravenous and oral administration to rats using LC/MS/MS(6) and the results indicated that the bioavailabilities (BA) of the four alkaloids
were very low - only about 10% after oral administration. Therefore, it is critical to enhance their BA for oral
administration in order to improve their clinic efficacy.
For a poorly water-soluble drug, it is important to
improve its absorption from the gastrointestinal (GI)
tract. Therefore, achieving a solution of the drug in the
GI fluid is a critical requirement. Solid dispersion (SD) is
a widely used method to enhance the oral BA for poorly
water-soluble drugs using different carriers, such as
surface-active carrier, polyethylene glycol (PEG) and poly
vinyl pyrrolidone (PVP)(7). In SD, the drug is dispersed in
water-soluble matrices either molecularly or as fine particles. The carrier is often used in large amount (more than
5 folds of the drug), which may result in a volume that is
too large to administer. Our previous pharmacokinetic
study using rats and dogs showed that if the volume was
too large, the rats and dogs vomited and scoured because
of GI stimulation. However, if the dosage volume was not
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large enough, the drug concentration in plasma or serum
would be too low to be determined. The LC/MS method
established by Li et al.(4), with the lowest limits of quantitation for four substances being 1 ng/mL in 0.1 mL of
rat plasma, had been used in our previous study for the
BAs of the four alkaloids. However, the method was not
valid for plasma determination after oral administration of the alkaloids SD to rats and dogs because of the
low drug concentration. In pharmacokinetics, it is an
important method to calculate the BA by determining
the cumulative urinary excretion of drugs. Therefore,
assay of the cumulative excretion of the alkaloids in urine
after administration should be an effective solution to the
problem mentioned above. In the present study, an SD
method was developed to improve the BAs of the alkaloids of the extract by improving their solubility. In addition, the BAs of the main alkaloids were calculated by
determining their amounts in urine using HPLC.

MATERIALS AND METHODS
I. Reagents and Chemicals
Dehydrocavidine (YHL-1), coptisine (YHL-2) and
dehydroapocavidine (YHL-3)(4) (Figure 1) reference
standards were purchased from the National Institute
for the Control of Pharmaceutical and Biological Products (Beijing, China). PEG 4000 and PVP K30 were
purchased from Shanghai Yunhong Chemical Industry
Co., Ltd. (Shanghai, China).
Acetonitrile was of LC grade (Fisher Scientific,
Massachusetts, Waltham, USA). Distilled and deionized
water was produced by a Milli-Q Reagent Water System
(Millipore, Bedford, MA, USA). All other chemicals
were of analytical reagent grade.
The alkaloids (AE) of the extract of Corydalis saxicola Bunting was provided by the 2nd Military Medical
University and was determined to contain 39.09%, 14.09%
and 28.08% of YHL-1, YHL-2 and YHL-3, respectively,
by HPLC/DAD.
II. Animals
Twenty SD rats, each weighing 180 - 220 g (10 males

CH3O

and 10 females), were purchased from Beijing Mars
Biotechnology Co., Ltd. (Beijing, China). The animals
were housed and cared for under a constant temperature of 22 ± 1°C and humidity of 50 ± 10%. Their diet
was prohibited for 2 days before the experiment while
water was available freely. The entire experiment was
performed in accordance with the regulations of the
Animal Ethical Committee of Tsinghua University.
III. HPLC Conditions
All analytical procedures were performed on an
Agilent 1100 HPLC/DAD system (Agilent Technologies
Inc., Beijing, China) equipped with an auto-injector. The
chromatographic separation was performed on an Apollo
C18 column (4.6 × 250 mm, 5 mm) maintained at 30°C.
The wavelength was 347 nm and the injection volume
was 20 mL.
The quantification method to assay the contents of AE
in tablets in our previous study was used to determine the
solubility(8). The mobile phase was acetonitrile - PBS (22 :
78, v/v). PBS consisted of 20 mmol of KH 2PO4, 10 mmol
of triethylamine and 2 mL of H3PO4 in 1 L (pH 2.3). The
flow rate was 0.8 mL/min and the run time was 35 min.
The quantification method for urine samples was
developed. The mobile phase was (A) acetonitrile and (B)
a solution of 2 mL of glacial acetic acid and 1.5 mL of
triethylamine in 1 L (pH 4.1). The gradient program was
as follows: 0 - 10 min, 25% A; 10 - 16 min, 25 → 35% A;
16 - 22 min, 35 → 60% A; 22 - 25 min, 60 → 25% A; 25 30 min, 25 → 25% A. The flow rate was 1.0 mL/min and
the re-equilibration time for the LC column was 2 min.
IV. Preparation of AE SD
(I) Melting Method
Three samples were prepared with different ratios of
AE (1 : 3, 1 : 5 and 1 : 7) with respect to the carrier, PEG
4000. PEG 4000 was placed into three test-tubes and the
tubes were immersed in a temperature-controlled bath at
65 - 70°C. At this elevated temperature, PEG 4000 was
liquefied. AE was added into each tube and the mixtures
were constantly stirred with micro-spatulas until
complete dispersion. The mixtures were poured onto

HO

O
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Figure 1. Chemical structures of three main alkaloids, Dehydrocavidine (YHL-1), Coptisine (YHL-2) and Dehydroapocavidine (YHL-3) of the
extract of Corydalis saxicola Bunting
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Three samples were prepared with different ratios of
AE (1 : 3, 1 : 5 and 1 : 7) with respect to the carrier, PVP
K30. PVP K30 was placed into three test-tubes, followed
by AE. The mixtures were constantly stirred and dissolved
in 10 folds of ethanol using micro-spatulas until complete
dissolution occurred. The ethanol was then evaporated and
the solid mixtures were dried in a desiccator containing
silicon gel for 48 h and ground into 80-mesh powders.

males and 5 females) each. 0.50 g of AE was dispersed in
100 mL of deionized water to obtain an AE suspension.
4.0 g of AE SD (AE : PEG 4000 = 1 : 7) was dissolved in
100 mL of deionized water to obtain AE SD solution. The
AE suspension and AE SD solution were treated by ultrasonication for 10 min (KQB-100, Kunshan Supersonic
Instrument Co., Kunshan, China).
For the first group, each rat was orally administered
with AE suspension (25.0 mg AE per kg body weight). For
the second group, each rat was orally administered with AE
SD solution (200 mg AE SD (equivalent to 25.0 mg AE) per
kg body weight). After administration, the diet for the rats
was prohibited for 24 h while water was taken freely. The
whole urine of each group was collected at 12 h and 24 h.

V. Characteristics of AE SD

(II) Preparation of Urine Samples

(I) Thermal Analysis

Urine samples were centrifuged at 4,500 rpm for 10
min at 4°C (TGL 16C, Medical Centrifuge Co., Beijing,
China). 100 mL of the upper layer was mixed with 400
mL of methanol using vortex for 3 min and then centrifuged at 4,500 rpm for 5 min at 4°C. The upper layer was
transferred to another tube and evaporated to dryness at
45°C under a gentle stream of nitrogen (purity > 99.5%).
The residue was reconstituted in 100 mL of methanol and
centrifuged at 10,000 rpm for 10 min at 4°C. 20 mL of
the supernatant was injected into the HPLC system for
analysis. The same sample handling process was used for
recovery and precision studies in urine.

glass plates and frozen at -20°C for 24 h. The mixtures
were then dried in a desiccator containing silicon gel for
48 h and ground into 80-mesh powders.
(II) Solvent Method

A STARe Evaluation differential scanning calorimetry (DSC) thermal analyzer (Mettler-Toledo Shanghai
Co., Shanghai, China) was used to obtain thermograms at
a heating rate of 10°C/min over the temperature range of
20 - 150°C. The samples ranged in weight from 3.2 to 5.7
mg and were sealed inside crimped aluminum pans.
(II) Powder X-ray Diffraction
The powder X-ray diffraction (XRD) patterns of
PEG 4000, AE, physical mixture and the SD with the
highest solubility in water were determined using a
multi-crystal X-ray diffractometer (Bruker Co., Berlin,
Germany) with monochromatized CuKa radiation. The
samples were analyzed between 20 angles of 5° and 60°.
(III) Physical and Chemical Stabilities
As a new formulation for administration, it was
important to ensure that the prepared AE does not chemically degrade or change its physical form over time.
Therefore, the stability of the SD in terms of color,
thermal analysis, X-ray diffraction and AE content of the
SD powder was tested over 0, 90 and 180 days.
(IV) Solubilities of AE and AE SD
The solubilities of AE and AE SD was determined in
water, pH 1.2 HCl and pH 7.2 PBS, according to the USP
paddle method (50 rpm at 37 ± 0.5°C). Aliquots of dissolution medium collected at 24 h were filtered through
0.45-mm syringe filters and analyzed by HPLC.
VI. Bioavailability of SD
(I) Oral Administration
The rats were divided into 2 groups with 10 rats (5

(III) Preparation of Calibration Standards and Calibration
Curves
The mixed standard stock solutions of YHL-1,
YHL-2 and YHL-3 were prepared in methanol and the
concentrations were 56.0, 32.0 and 60.0 mg/mL, respectively. A series of standard working solutions with
concentrations in the range of 0.280 - 5.60, 0.160 - 3.20,
and 0.300 - 6.00 mg/mL for YHL-1, YHL-2, and YHL-3,
respectively, were obtained by further diluting the standard stock solution with methanol. All solutions were
stored at 4°C. A series of 100-mL standard working solutions were evaporated to dryness at 45°C under a gentle
stream of nitrogen. The residues were reconstituted in
100 mL of blank urine to prepare the calibration standards
by the same method used for urine sample preparation.
Linearity of calibration was tested by extraction and
assayed as described above (n = 3). Calibration curves for
YHL-1, YHL-2 and YHL-3 in the concentration ranges
were obtained by plotting the peak area versus concentration in urine. Unknown concentrations of YHL-1, YHL-2
and YHL-3 were determined with reference to the calibration curves.
(IV) Assay Precision, Stability of Urine Samples and
Analytical Recovery
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The quantification method previously established for
solubility assay was relatively simple and the excipients
in SD produced no interference for the three compounds.
However, the method was unsuitable for urine sample
determination and the internal components could significantly affect the separation. Therefore, the HPLC method
with gradient elution was established.

Quality control (QC) samples were prepared in the
same way as calibration standards with blank urine. The
nominal concentrations were 0.280, 1.40 and 5.60 mg/
mL for YHL-1, 0.160, 0.800 and 3.20 mg/mL for YHL-2,
and 0.300, 1.50 and 6.00 mg/mL for YHL-3, which corresponded to the low (LQC), medium (MQC) and high
(HQC) levels of the calibration curves. The samples were
stored at -80°C until analysis. Intra-day precision was
tested by analyzing the QC samples at different times
of the same day. Inter-day precision was determined by
repeated analysis of the same samples over three consecutive days. The precision was evaluated by RSD (%) of
peak areas of the three standards.
The stability of the urine samples was examined at
room temperature for 0, 4, 8 and 20 h. The amounts of
YHL-1, YHL-2 and YHL-3 in the urine samples were
determined using newly prepared calibration curves.
The analytical recovery of the extraction procedure for
YHL-1, YHL-2 and YHL-3 from rat urine was determined
by spiking 100-mL aliquots of drug-free urine with various
amounts of YHL-1, YHL-2 and YHL-3. Urine samples were
spiked with 0.280, 1.40 and 5.60 mg/mL of YHL-1, 0.160,
0.800 and 3.20 mg/mL of YHL-2, and 0.300, 1.50 and 6.00
mg/mL of YHL-3, and extracted according to the method
described above (n = 3 at each level). Standard mixtures of
YHL-1, YHL-2 and YHL-3 equivalent to the concentrations
in the urine samples were directly injected into the HPLC
system. The recovery was evaluated by comparing the peak
areas of the urine extracts to that of the standard mixtures.

The solubilities of YHL-1, YHL-2 and YHL-3 of
AE and AE SD in water, pH 1.2 HCl and pH 7.2 PBS are
shown in Table 1. The data were statistically analyzed
with t-test. The results indicated that YHL-1, YHL-2 and
YHL-3 of AE had poor solubility in the three solvents.
The physical mixtures of AE with PEG 4000 or PVP K30
could not significantly enhance the solubility of AE ( p >
0.05). However, with the increase of the amount of PEG
4000 or PVP K30, the solubility of the physical mixtures
was improved. The reason was that PEG 4000 and PVP
K30 are weak solubilizing agents. As for AE SD, solubility could be greatly improved in any solvent mentioned
above, especially for the SD consisting of AE and PEG
4000 (1 : 7). The melting method with PEG was simpler
than the solvent method in manufacturing processes of
large industrial scale. Furthermore, the melting method
produced no liquid or gas waste. Therefore, it was
selected to prepare AE SD and the prepared AE SD with
AE : PEG 4000 ratio of 1 : 7 was further studied.

(V) Assay of Samples

III. Thermal Analysis of AE SD

The present method was used to determine the
concentrations of YHL-1, YHL-2 and YHL-3 in rat urine
collected during 0 - 12 h and 12 - 24 h, after oral administration of AE suspension and AE SD solution. The
concentrations of YHL-1, YHL-2 and YHL-3 were determined using the linear regression equations obtained
from the calibration curves.
The percentages of the excreted components from
urine following oral administration were evaluated. The
RE BA of AE SD solution compared with AE suspension
was calculated by the following equation:

The DSC spectra of PEG 4000, AE, physical
mixture of AE and PEG 4000 (1 : 7), and SD of AE and
PEG 4000 (1 : 7) are shown in Figures 2 A, B, C and D,
respectively. The corresponding peak temperatures were
64.2, 58.8, 63.7 and 62.3°C. It was found that AE led to a
decrease in the melting point of PEG 4000 and the difference between the physical mixture and SD was minimal.
The results also indicated that the method of DSC was
not suitable for AE SD, because the melting point of PEG
4000 was 55 - 60°C and during the DSC analysis, the
amount of drug present in the formulation dissolved in
the matrix at about 60°C(7).

REBA =

Con.AESD × VAESD / DoseAESD
× 100%
Con.AE × VAE / DoseAE

where Con.AESD and Con.AE refer to the total
concentrations of AE SD and AE in rat urine, respectively, and VAESD and VAE are the total volumes of the
collected urine after oral administration of AE SD solution and AE suspension, respectively.

RESULTS AND DISCUSSION
I. HPLC Conditions

II. Solubility of AE SD

IV. Powder X-ray Diffraction of AE SD
The X-ray diffraction spectra of PEG 4000, AE,
physical mixture of AE and PEG 4000 (1 : 7), and SD
of AE and PEG 4000 (1 : 7) are shown in Figures 3 A,
B, C and D, respectively. The spectra of PEG 4000 and
AE were significantly different. The theta scales of
8.34, 11.58 were disappeared in the spectrum of AE SD
compared with the physical mixture, indicating that in
the SD formulation the drug might be in a dissolved or
amorphous state, which was different from that in physical mixture.
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Figure 2. DSC of (A) PEG 4000, (B) the main alkaloids of the extract (AE) of Corydalis saxicola Bunting, (C) the physical mixture of AE and
PEG 4000 (1 : 7), and (D) the solid dispersion of AE and PEG 4000 (1 : 7)
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Figure 3. X-ray diffraction spectra of (A) PEG 4000, (B) the main alkaloids of the extract (AE) of Corydalis saxicola Bunting, (C) the physical
mixture of AE and PEG 4000 (1 : 7), and (D) SD of AE and PEG 4000 (1 : 7)
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V. Physical and Chemical Stabilities of AE SD
The color of AE SD was light yellow. The contents
of YHL-1, YHL-2 and YHL-3 in AE SD were 4.81 ±
0.21%, 1.73 ± 0.08% and 3.40 ± 0.15% (n = 3), respectively. After 90d and 180d, the color, thermal analysis,
X-ray diffraction and the AE content of the AE SD
powder, which was stored in a desiccator containing
silicon gel, did not show any difference. This indicated
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that AE SD was stable within 180d. When AE SD is
further developed into tablet dosage form, the use of
other excipients, such as lactose, starch, or micro crystal
cellulose (9), can further disperse the AE SD. Besides, the
tablets can be coated with film to avoid the influence of
light, moisture, or oxygen, etc.(10) These measures can
significantly improve the stability of the AE SD.
VI. Method Validation for Urine Sample Determination
The calibration curves of YHL-1, YHL-2 and YHL-3
were constructed in the ranges of 0.280 - 5.60 mg/mL,
0.160 - 3.20 mg/mL and 0.300 - 6.00 mg/mL, respectively. The regression equations of the curves were calculated as follows: YHL-1: y = 29.084χ - 0.9259 (correlation coefficient r = 0.9993), YHL-2: y = 30.418χ - 2.109
(r = 0.9992), and YHL-3: y = 30.013χ - 1.915 (r = 0.9992),
where χ was the concentration of the compound (mg/
mL) and y was the peak area. They showed good linear
relationships between y and χ in the ranges above. The
assay was considered adequately specific as no endogenous urine components eluted at the same retention time
as that of the analytes of interest (Figure 4). The three
compounds were eluted in the order, YHL-3, YHL-2 and
YHL-1, with good resolution.
The limit of detection (LOD) and the limit of quantification (LOQ) were determined at the lowest concentration based on S/N of 3 and 10, respectively (11). The LOD
and LOQ of YHL-1, YHL-2 and YHL-3 were 0.0093,
0.0081 and 0.0102 mg/mL, and 0.028, 0.026, and 0.031
mg/mL, respectively.
The intra-day and inter-day precision results of
YHL-1, YHL-2 and YHL-3 are shown in Table 2. Each
RSD value was less than 3%, indicating good precision.
Inter-day precision was consistently higher than intraday precision, which could be due to systematic errors
from sample treatment and the instrument.
The stability was expressed as a percentage of
nominal concentration. After standing at room temperature for 20 h, the concentrations relative to the initial
ones (n = 3) of YHL-1, YHL-2 and YHL-3 were 98.16%,
97.88% and 98.32%, respectively, and the corresponding
RSDs were 1.88%, 2.41% and 2.03%. The results showed
that the samples were stable at room temperature.
The recovery data of YHL-1, YHL-2 and YHL-3
are shown in Table 3. For the different samples with
high, middle and low concentrations, recoveries were all
higher than 90%, indicating that the liquid-liquid extraction method established was simple, rapid and could
extract most of YHL from rat urine.
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Figure 4. HPLC chromatograms of YHL-1, YHL-2 and YHL-3 in
rat urine samples at 0 - 12 h after oral administration of AE SD (A:
Blank urine sample; B: Blank urine spiked with standards; C: Urine
sample)

VII. Bioavailability of AE SD
The assay method was successfully used to quantitatively measure the concentrations of YHL-1, YHL-2
and YHL-3 in urine samples obtained from rats orally
administered separately with AE suspension and AE

412

YHL-3

94.17 ± 4.88

0.280

94.48 ± 0.98

3.20

93.07 ± 4.62

0.800

91.33 ± 5.31

0.160

92.57 ± 5.19

6.00

95.33 ± 3.17

1.50

93.81 ± 4.91

0.300

94.38 ± 5,18

191.4
2.69 ± 2.07*
189 ± 145*
297.7
1.85 ± 1.09*
130 ± 76.5*
107.3
0.843 ± 0.800

32.2 ± 22.6*
286.2
0.589 ± 0.332*
20.8 ± 11.7*
110.1
0.323 ± 0.254

189.2
1.18 ± 1.02*
73.0 ± 75.5*

0.749 ± 0.774*

300.4

116 ± 99.5*

1.41 ± 1.16
98.5 ± 81.5

0.499 ± 0.410
17.6 ± 14.5

0.626 ± 0.477
61.0 ± 46.5

Amount
excreted (%)
Cumulative amount
in urine (mg/kg)

0 - 24 h

RE BA
(%)

115.7
0.434 ± 0.479

59.0 ± 56.0

1.40

YHL-3: 7.02

95.12 ± 3.34

11.4 ± 8.95

5.60

YHL-2: 3.52

YHL-2

Recovery (%)

42.3 ± 46.7

YHL-1

Concentration (mg/mL)

YHL-1: 9.77

Component

200

Table 3. Recovery of YHL-1, YHL-2 and YHL-3 from rat urine (n = 3)

10

1.59

AE SD

1.45

0.621 ± 0.506

0.300

43.5 ± 35.5

0.66

0.786 ± 0.592

0.31

55.0 ± 41.5

1.50

YHL-3: 7.02

0.97

0.206 ± 0.157

0.22

7.25 ± 5.55

6.00

0.294 ± 0.267

1.77

10.4 ± 9.40

1.98

YHL-2: 3.52

0.160

0.249 ± 0.323

1.18

24.3 ± 31.5

0.41

0.375 ± 0.310

0.800

36.6 ± 30.25

0.93

YHL-1: 9.77

0.25

25.0

3.20

10

1.63

AE

1.49

Amount
excreted (%)

0.280

Cumulative amount
in urine (mg/kg)

0.57

RE BA
(%)

0.33

Amount
excreted (%)

1.40

Cumulative amount
in urine (mg/kg)

0.65

Dose of YHL
(mg/kg)

0.25

Dose
(mg/kg)

5.60

n

YHL-3

Inter-day
precision
(% RSD)

Group

YHL-2

Intra-day
precision
(% RSD)

12 - 24 h

YHL-1

Nominal
concentration
(mg/mL)

0 - 12 h

Component

Table 4. RE BAs of YHL-1, YHL-2 and YHL-3 of AE SD (AE/PEG 4000, 1 : 7) compared with AE after oral administration to rats (n = 3)

Table 2. Intra-day and inter-day precision results of YHL-1, YHL-2
and YHL-3 determined with HPLC/DAD (n = 5)

RE BA
(%)

SD solution. From 24 h to 36 h, no YHL-1, YHL-2 and
YHL-3 could be determined in gathered urine. Therefore, the urine was gathered from 0 - 12 h and 12 - 24 h.
The results are shown in Table 4. The amount excreted
was reflected by the recovery of the dosage in urine.
For YHL-1, the RE BA of AE SD after oral administration were 115.7% at 12 h and 300.4% at 24 h. These
were compared with the RE BA of AE after oral administration. It was interesting to note that the total amounts
excreted for AE suspension and AE SD solution were
similar at 12 h after administration. However, the amount
excreted for AE SD was significantly higher than that
of AE at 24 h ( p < 0.05), indicating that AE SD could

0.912 ± 0.640* 182.7
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improve the RE BA at 12 - 24 h after administration. The
total RE BA of AE SD from 0 - 24 h was about twice that
of AE ( p < 0.05). The results were also similar for YHL-2
and YHL-3. The results could also indirectly indicate
that the absolute BA could be enhanced for the three
poorly water-soluble components by formulating SD with
PEG 4000 as the carrier.

CONCLUSIONS
The SD technique was used to improve the solubility
of the alkaloid components YHL-1, YHL-2 and YHL-3 in
the extract of Corydalis saxicola Bunting. The formulation of SD with AE and PEG 4000 (1 : 7) could significantly improve the solubility of AE in water, pH 1.2 HCl
and pH 7.2 PBS. The method of cumulative quantification of urine samples was successfully used in the evaluation of the BAs of the components. A HPLC method
was established to determine YHL-1, YHL-2 and YHL-3
in rat urine after oral administration. The results of the
validation showed that the established HPLC method
had good selectivity, sensitivity and repeatability. The
production of AE SD was relatively simple and AE SD
could be further made into tablet form with large industrial scale.
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